
#TILTuesday -- Stage IV melanoma warrior, Hillary Castaneda, was diagnosed in October 2021 prior to FDA approval of a revolutionary immunotherapy known as Tumor-infiltrating lymphocyte (TIL) therapy in 2024. Following a 2025 recurrence, Hillary underwent one round of TIL therapy and a year later is showing no evidence of disease! youtu.be/tDvufNLR7ZE In this #TILTuesday installment, Hillary underscores the importance of advocating for yourself with your care team and shares her inspirational and personal advanced #melanoma journey. Hillary's story also denotes the power of innovative research and treatments such as TIL that provide hope to patients with melanoma that can't be treated with surgery alone for metastatic melanoma patients. #ProgressIsPower You can learn more about TIL therapy by visiting melanoma.org.





















